Abstracts

HIV DRUG RESISTANCE IN CASES OF PERINATAL TRANSMISSION IN IMPAACT 2010 (VESTED)

Background: VESTED was a multicenter open-label, randomized phase III trial comparing the safety and efficacy of dolutegravir (DTG)- and efavirenz (EFV)-based regimens in pregnant and breastfeeding women. Perinatal transmission to the infant occurred in 4/617 (0.6%) mother-infant pairs. This sub-study evaluated HIV drug resistance (HIVDR) in these 4 mother-infant pairs. Methods: Pregnant women with HIV…

HIV VIRAL LOAD AND TIME-TO-COVID-19 VACCINATION AMONG PEOPLE WHO INJECT DRUGS

Background: Structural barriers to care among people who inject drugs (PWID) raise concerns about disproportionate access to essential services like COVID-19 vaccination. Given the heightened risk of serious complications resulting from SARS-CoV-2 infection, particularly among people living with HIV (PWH) with unsuppressed viral load, its critical to understand the role of HIV care among other…

KINETICS OF HBV RNA AND CORE-RELATED ANTIGEN LEVELS IN PLWH WITH FUNCTIONAL HBV CURE

Background: The determinants of functional cure of hepatitis B virus (HBV) infection during antiviral therapy are poorly understood. Hepatitis B core-related antigen (HBcrAg) and circulating HBV RNA correlate with intrahepatic covalently closed circular DNA (cccDNA) levels and cccDNA transcriptional activity. Both markers may help identify persons who eventually experience functional HBV cure on therapy. We…

INITIAL SUPPLEMENTAL DOLUTEGRAVIR DOSE IN SECOND-LINE ART: A PHASE 2 RANDOMISED TRIAL

Background: Dolutegravir concentrations are reduced by the induction effect of efavirenz, necessitating twice daily dolutegravir dosing when co-administered. Efavirenz induction persists for several weeks after stopping, which could select for resistance if switching occurred with unsuppressed HIV-1 RNA levels. We evaluated the need for a lead-in supplemental dolutegravir dose in adults failing first-line antiretroviral therapy…